Juvenile spondyloarthritis treatment recommendations

American Journal of the Medical Sciences

Volumn 343, Issue 5, 2012, Pages 367-370

  Tse, Shirley M L ^a   Burgos Vargas, Ruben ^b   Colbert, Robert A ^c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HOSPITAL GENERAL DE MÉXICO   (Mexico)

^c NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Axial; Enthesitis related arthritis; Juvenile spondyloarthritis

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; CLINICAL FEATURE; CLINICAL PROTOCOL; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENTHESITIS; ERYTHROCYTE SEDIMENTATION RATE; EVIDENCE BASED MEDICINE; HEALTH CARE ORGANIZATION; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; JUVENILE SPONDYLOARTHRITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SACROILIITIS; SPINE DISEASE; SPINE RADIOGRAPHY; SPONDYLARTHRITIS; SYMPTOM; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84860799349     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3182514043     Document Type: Conference Paper

References (41)

1. Jarrett SJ, Sivera F, Cawkwell LS, et al. MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumor necrosis factor therapy after a short course of etoricoxib. Ann Rheum Dis 2009;68:1466-9.
2. Wanders A, Heijde D, Landewé R, et al. Nonsteroidal antiinflamma-tory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005;52:1756-65. (Pubitemid 40852884)
3. Burgos-Vargas R, Vaquez-Mellado J, Pacheo-Tena C, et al. A 26 week randomized, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis 2002;61:941-2.
4. Huang JL, Chen LC. Sulphasalazine in the treatment of children with chronic arthritis. Clin Rheumatol 1998;17:359-63.
5. Imundo LF, Jacobs JC. Sulfasalazine therapy for juvenile rheumatoid arthritis. J Rheumatol 1996;23:360-6. (Pubitemid 26078395)
6. Job-Deslandre C, Menkes CJ. [Treatment of juvenile spondyloarthro-pathies with sulfasalazine]. Rev Rhum Ed Fr 1993;60:489-91.
7. Suschke HJ. [Treatment of juvenile spondyloarthritis and reactive arthritis with sulfasalazine]. Monatsschr Kinderheilkd 1992;140:658-60.
8. van Rossum MA, Fiselier TJ, Franssen MJ, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 1998;41:808-16. (Pubitemid 28225780)
9. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999;42:2325-9. (Pubitemid 30333412)
10. Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2004-12.
11. Dougados M, Boumier P, Amor B. Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. Br Med J (Clin Res Ed) 1986;293:911-4. (Pubitemid 16002427)
12. Dougados M, vam der Linden S, Leirisalo-Repo M, et al. Sulfasala-zine in the treatment of spondyloarthropathy: a randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618-27.
13. Nissila M, Lehtinen K, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum 1988;31:1111-6.
14. Song IH, Hermann K, Haibel H, et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomized controlled trial. Ann Rheum Dis 2011;70:590-6.
15. Braun J, van der Horst-Bruinsma IE, Huang F, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 2011;63:1543-51.
16. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med 1992;326:1043-9.
17. Ruperto N, Murray KJ, Gerloni V, et al; Pediatric Rheumatology International Trials Organization. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004;50:2191-201. (Pubitemid 38924397)
18. Woo P, Southwood TR, Prieur AM, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000;43: 1849-57.
19. Burgos-Vargas R, Casasola-Vargas J, Gutierrez-Suarez R, et al. Efficacy, safety, and tolerability of infliximab in juvenile-onset spondy-loarthropathies (JO-SpA): results of a three-month, randomized, double-blind, placebo-controlled trial phase. Arthritis Rheum 2007;56(suppl): S319.
20. Burgos-Vargas R, Casasola-Vargas J, Gutierrez-Suarez R. A 3-month, double-blind, placebo-controlled, randomized trial of infliximab in juvenile-onset spondyloarthritis (SpA) and a 52-week open extension. Clin Exp Rheumatol 2008;26:745.
21. Schmeling H, Horneff G. Infliximab in two patients with juvenile ankylosing spondylitis. Rheumatol Int 2004;24:173-6. (Pubitemid 38797633)
22. Tse SM, Burgos-Vargas R, Laxer RM. Anti-tumor necrosis factor alpha blockage in the treatment of juvenile spondyloarthropathy. Arthritis Rheum 2005;52:2103-8. (Pubitemid 40994333)
23. Tse SM, Burgos-Vargas R, O'Shea F, et al. Long term outcome of anti-TNF therapy in juvenile spondyloarthropathy. Arthritis Rheum 2007;56:898.
24. Henrickson M, Reiff A. Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. J Rheumatol 2004;31:2055-61. (Pubitemid 39336735)
25. Sulpice M, Deslandre CJ, Quartier P. Efficacy and safety of TNF-alpha antagonist therapy in patients with juvenile spondyloarthropa-thies. Joint Bone Spine 2009;76:24-7.
26. van der Heijde D, Landewé R, Baraliakos X, et al; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008;58:3063-70.
27. van der Heijde D, Landewé R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324-31. (Pubitemid 351705922)
28. Baraliakos X, Listing J, Brandt J, et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford) 2007;46:1450-3. (Pubitemid 47317093)
29. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011;63:465-82.
30. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 2005;52:1000-8. (Pubitemid 40530105)
31. Guglielmi G, Cascavilla A, Scalzo G, et al. Imaging findings of sacroiliac joints in spondyloarthropathies and other rheumatic conditions. Radiol Med 2011;116:292-301.
32. Rudwaleit M, Jurik AG, Hermann KG, et al. Defining active sacroi-liitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 2009;68:1520-7.
33. Rudwaleit M, Landewé R, van der Heijde D, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009;68:770-6.
34. Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777-83.
35. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 2002;359:1187-93. (Pubitemid 34304258)
36. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spon-dylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346:1349-56. (Pubitemid 34754607)
37. van der Heijde D, Kivitz A, Schiff MH, et al; ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54: 2136-46. (Pubitemid 44051069)
38. Inman RD, Davis JC Jr, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58:3402-12.
39. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904.
40. van der Heijde, Sieper J, Maksymowych WP, et al; Assessment of SpondyloArthritis international Society. 2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70: 905-8.
41. Hofer M. Spondyloarthropathies in children\are they different from those in adults? Best Pract Res Clin Rheumatol 2006;20: 315-28.